Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 2013Carcinoma, Non-Small-Cell Lung 1228Breast Neoplasms 1215Leukemia, Myeloid, Acute 969Neoplasm Metastasis 903Melanoma 778Colorectal Neoplasms 752Multiple Myeloma 725Lymphoma 725Ovarian Neoplasms 675Pancreatic Neoplasms 665Prostatic Neoplasms 659Lymphoma, Non-Hodgkin 659Recurrence 637Precursor Cell Lymphoblastic Leukemia-Lymphoma 585Lung Neoplasms 560Leukemia, Lymphocytic, Chronic, B-Cell 555Glioblastoma 528Leukemia 486Lymphoma, Large B-Cell, Diffuse 441Lymphoma, Follicular 420Brain Neoplasms 415Squamous Cell Carcinoma of Head and Neck 389Stomach Neoplasms 388Carcinoma, Renal Cell 385Myelodysplastic Syndromes 382Carcinoma, Hepatocellular 368Advanced Solid Tumors 358Lymphoma, Mantle-Cell 345Glioma 344

Interventions

ribociclib 1LSZ102 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Interventional × Advanced or Metastatic ER+ Breast Cancer × Clear all
NCT02734615 2022-08-01

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Novartis

Phase 1 Terminated
199 enrolled
Breast

Advanced or Metastatic ER+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡